World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
29790
World Ranking
14978
National Ranking
7571

Overview

Partow Kebriaei is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, with a significant concentration in hematology and oncology. Additional areas of study include public health, environmental and occupational health, molecular biology, and genetics.

The scientist's work covers a range of key topics, notably:

  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • CAR-T cell therapy research
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Chronic Lymphocytic Leukemia Research

Among Partow Kebriaei's recent publications are:

  • "Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors," 2020, New England Journal of Medicine
  • "Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial," 2024, Nature Medicine
  • "Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma," 2021, Blood
  • "Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma," 2020, Blood Advances
  • "Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial," 2023, Nature Medicine

Frequent coauthors collaborating with Partow Kebriaei include:

  • Elizabeth J. Shpall
  • Richard E. Champlin
  • Muzaffar H. Qazilbash
  • Samer A. Srour
  • Uday Popat

Kebriaei's work is often published in academic journals such as:

  • Blood
  • Transplantation and Cellular Therapy
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • American Journal of Hematology

The scientist's research includes over 900 publications in the broad field of medicine, with more than 400 focused on hematology. Contributions to oncology and public health studies also form a substantial part of their scholarly output.

Best Publications

  • Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Sattva S. Neelapu;Sudhakar Tummala;Partow Kebriaei;William Wierda

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Enli Liu;David Marin;Pinaki Banerjee;Homer A. Macapinlac

  • Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex

    David L. Rimm;Erika R. Koslov;Partow Kebriaei;Carol D. Cianci

  • A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

    Hiroki Torikai;Andreas Reik;Pei Qi Liu;Yuanyue Zhou

  • Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

    Ann M. Leen;Catherine M. Bollard;Adam M. Mendizabal;Elizabeth J. Shpall

  • Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease

    Partow Kebriaei;Luis Isola;Erkut Bahceci;Kent Holland

  • Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

    Partow Kebriaei;Harjeet Singh;M. Helen Huls;Matthew J. Figliola

  • Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

    Marcos J.G. de Lima;Ian McNiece;Simon N. Robinson;Mark Munsell

  • Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

    Lenka V. Hurton;Lenka V. Hurton;Harjeet Singh;Amer M. Najjar;Kirsten C. Switzer

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

    Farhad Ravandi;Susan O'Brien;Deborah Thomas;Stefan Faderl

  • Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

    Hiroki Torikai;Andreas Reik;Frank Soldner;Edus H. Warren

  • Results of Inotuzumab Ozogamicin, a CD22 Monoclonal Antibody in Refractory and Relapsed Acute Lymphocytic Leukemia

    Hagop Kantarjian;Deborah Thomas;Jeffrey Jorgensen;Partow Kebriaei

  • Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

    Stefan Octavian Ciurea;Victor Eduardo Mulanovich;Rima M Saliba;Ulas D. Bayraktar

  • Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

    Antonio Di Stasi;Denái R. Milton;L.M. Poon;Amir Hamdi

  • Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

    Farhad Ravandi;Jeffrey L. Jorgensen;Deborah A. Thomas;Susan O'Brien

  • Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

    Farhad Ravandi;Susan M. O'Brien;Jorge E. Cortes;Deborah M. Thomas

  • Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

    Elias Jabbour;Sergio Giralt;Hagop Kantarjian;Guillermo Garcia-Manero

  • Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies

    Harjeet Singh;Matthew J. Figliola;Margaret J. Dawson;Helen Huls

  • Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD

    P.J. Martin;J.P. Uberti;R.J. Soiffer;H. Klingemann

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Borje S. Andersson
Borje S. Andersson The University of Texas MD Anderson Cancer Center
Marcos de Lima
Marcos de Lima The Ohio State University
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Katayoun Rezvani
Katayoun Rezvani The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine but want additional pathways or flexibility, there are several online degrees and certifications that can open doors to rewarding healthcare careers. These programs offer opportunities both for entry-level positions and for professionals seeking to advance in the field.

For those interested in pharmaceuticals, a pharmacy degree online can lead to diverse careers in clinical, retail, or research settings. This route can be especially valuable for students requiring a flexible schedule.

Another in-demand specialization is Health Information Management. Earning a him degree online allows you to work in managing medical records, data privacy, and hospital information systems.

Medical billing and coding offer a non-clinical yet vital role in healthcare administration. Discover more about medical billing and coding certification cost and how affordable it can be to get certified quickly and start working from anywhere.

Aspiring advanced practice nurses can benefit from the cheapest nurse practitioner programs that provide both affordability and convenience for working professionals.

Whether your passion leads you to clinical care, healthcare administration, or technology, these online programs offer accessible routes to enter and progress in the medical field.

Best Scientists Citing Partow Kebriaei

Trending Scientists